A Phase 1/2 interventional study of ARCT-165 and ARCT-154 in COVID-19, SARS-CoV-2 Infection and Corona Virus Infection, sponsored by Arcturus Therapeutics, Inc.. Completed at 4 sites in 3 countries. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-15.
Sponsored by Arcturus Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,860 studies in COVID-19 with a site in United States, this one is the 710th largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 62 in phase 1/2, and was the 1,250th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,860 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 482 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 92 across the 1,322 interventional studies, 300 across the 521 observational. Of the 1,415 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,860 have an industry lead sponsor. The 10 most frequent:
Arcturus Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Arcturus Therapeutics, Inc. has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
84 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,860 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2.
The study will initially enroll approximately 72 adult participants into 2 cohorts (A and B). Cohort A is further sub-divided into two sub-cohorts which include 12 participants who are seronegative, not previously vaccinated at screening (Sub-cohort A1) and 24 participants who are seropositive, not previously vaccinated at screening (Sub-cohort A2).
Within the first cohort (Cohort A), Sub-cohort A1 will include a total of 12 adult participants ≥21 to ≤65 years of age who have not been previously vaccinated with a SARS-CoV-2 vaccine. Sub-cohort A2 will include a total of 24 adult participants ≥21 to ≤65 years of age who have not been previously vaccinated with a SARS-CoV-2 vaccine. Study vaccines will be given as 2 doses separated by 28 days.
The second cohort (Cohort B) will include a total of 36 adult participants ≥21 to ≤65 years of age who have been previously vaccinated (5 months or longer prior to study enrollment) with SARS-CoV-2 vaccine. Study vaccines will be given as single doses.
Additional cohorts may increase the age range of participants up to 80 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals who:
Exclusion Criteria:
Individuals who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one dose of ARCT-165 on Day 1 and one dose of ARCT-165 on Day 29
Biological: ARCT-165
Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29
Biological: ARCT-154
Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29
Biological: ARCT-021
Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29
Biological: ARCT-021
Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29
Biological: ARCT-154
Participants will receive one dose of ARCT-165 on Day 1
Biological: ARCT-165
Participants will receive one dose of ARCT-154 on Day 1
Biological: ARCT-154
Participants will receive one dose of ARCT-021 on Day 1
Biological: ARCT-021
Dose 3
Dose 2
Dose 1
Number of Participants Reporting Solicited Local or Systemic Adverse Events (AEs)
Solicited local AEs were defined as injection site erythema, injection site pain, injection site induration, and injection site tenderness. Solicited systemic AEs were defined as arthralgia, chills, diarrhea, dizziness, fatigue, fever (categorized by measured body temperature), headache, myalgia, nausea and vomiting. Data are reported for the number of participants with solicited local and solicited systemic AEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to Day 8 (7 days after first vaccine administration for Cohorts A1, A2 and B), and up to Day 36 (7 days after second vaccine administration for Cohorts A1 and A2)
Number of Participants Reporting Unsolicited AEs
Unsolicited AEs were defined as any spontaneously reported or discovered AE. Data are reported for the number of participants with unsolicited AEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to Day 29 (28 days after vaccine administration for Cohort B), and up to Day 57 (up to 28 days after each vaccine administration for Cohorts A1 and A2)
Number of Participants Reporting Medically Attended Adverse Events (MAAEs), AEs Leading to Discontinuation From Study Vaccine/Study Withdrawal, or Serious Adverse Events (SAEs)
An MAAE was an AE that led to an unscheduled visit (including a telemedicine visit) with a health care provider (HCP) (e.g., nurse, nurse practitioner, physician's assistant, physician), including visits to a study site for unscheduled assessments (e.g., rash assessment, abnormal laboratory follow up, coronavirus disease 2019 \[COVID-19\]) and visits to HCPs external to the study site (e.g., urgent care, primary care physician). An SAE was defined as any event that resulted in death, was immediately life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Through Final Visit (365 days after last study vaccine dose); up to a maximum of approximately 394 days
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Serum Neutralizing Antibody Levels, Expressed as Geometric Mean Concentration (GMC)
Blood samples were collected to assess participants' immune response. GMC data are reported for the pseudoviral D614G variant. Data are reported in international units per milliliter (IU/mL).
Time frame: Baseline, Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2; Baseline, Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as GMC
Blood samples were collected to assess participants' immune response. GMC data are reported for the pseudoviral B.1.351 (beta) variant. Data are reported in arbitrary units per milliliter (AU/mL).
Time frame: Baseline, Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2; Baseline, Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as Geometric Mean Fold Rise (GMFR)
Blood samples were collected to assess participants' immune response. GMFR data are reported for the pseudoviral D614G variant.
Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as GMFR
Blood samples were collected to assess participants' immune response. GMFR data are reported for the pseudoviral B.1.351 (beta) variant.
Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Serum Neutralizing Antibody Levels (Pseudoviral D614G Variant)
Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G variant.
Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Serum Neutralizing Antibody Levels (Pseudoviral B.1.351 [Beta] Variant)
Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral B.1.351 (beta) variant.
Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
GMC Ratio (ARCT-165 vs ARCT-154 and ARCT-021 vs ARCT-154)
Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G Variant, B.1.351 Variant, B.1.617.2 Variant, BA.1 Variant for the GMC ratio of ARCT-165 vs ARCT-154 and ARCT-021 vs ARCT-154. Data are reported for the ARCT-165 and ARCT-021 arms (vs ARCT-154 values).
Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
GMC Ratio (ARCT-021 vs ARCT-165 Cohorts A1 and B)
Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G Variant, B.1.351 Variant, B.1.617.2 Variant, BA.1 Variant for the GMC ratio of ARCT-021 vs ARCT-165. Data are reported for the ARCT-021 arm (vs ARCT-165 values).
Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohort A1, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
SARS-CoV-2 Full-length Spike and Receptor-binding Domain (RBD) Binding Antibody Levels, Expressed as GMCs
Spike binding antibody levels expressed as GMCs are reported for ancestral, D614G, and B.1.351 variants and RBD binding antibodies for ancestral strain.
Time frame: Baseline and Day 57 for Cohorts A1 and A2, Baseline and Day 15 for Cohort B
Changes in SARS-CoV-2 Full-length Spike and RBD Binding Antibody Levels, Expressed as GMFRs
Spike binding antibody levels expressed as GMFRs are reported for ancestral, D614G, and B.1.351 variants and RBD binding antibody levels expressed as GMFR for ancestral strain.
Time frame: Day 57 for Cohorts A1 and A2, Day 15 for Cohort B
Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Full-length Spike and RBD Binding Antibody Levels
Data are reported for ancestral, D614G, and B.1.351 variants for Spike binding antibodies and ancestral for RBD binding antibodies.
Time frame: Day 57 for Cohorts A1 and A2, Day 15 for Cohort B
| Milestone | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 6 | 18 | 12 | 12 | 12 |
| Received at least 1 dose of study drug | 4 | 4 | 4 | 6 | 18 | 12 | 12 | 12 |
| Completed | 4 | 2 | 4 | 5 | 17 | 9 | 12 | 12 |
| Not completed | 0 | 2 | 0 | 1 | 1 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
Solicited local AEs were defined as injection site erythema, injection site pain, injection site induration, and injection site tenderness. Solicited systemic AEs were defined as arthralgia, chills, diarrhea, dizziness, fatigue, fever (categorized by measured body temperature), headache, myalgia, nausea and vomiting. Data are reported for the number of participants with solicited local and solicited systemic AEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Any Solicited Local AE After Dose 1 | 3 | 4 | 3 | 5 | 10 | 12 | 10 | 10 |
| Any Solicited Local AE After Dose 2 | 2 | 2 | 4 | 6 | 10 | — | — | — |
| Any Solicited Systemic AE After Dose 1 | 3 | 3 | 1 | 5 | 9 | 12 | 9 | 11 |
| Any Solicited Systemic AE After Dose 2 | 2 | 2 | 3 | 5 | 10 | — | — | — |
Unsolicited AEs were defined as any spontaneously reported or discovered AE. Data are reported for the number of participants with unsolicited AEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Unsolicited AEs | 3 | 3 | 2 | 4 | 15 | 9 | 9 | 10 |
An MAAE was an AE that led to an unscheduled visit (including a telemedicine visit) with a health care provider (HCP) (e.g., nurse, nurse practitioner, physician's assistant, physician), including visits to a study site for unscheduled assessments (e.g., rash assessment, abnormal laboratory follow up, coronavirus disease 2019 \[COVID-19\]) and visits to HCPs external to the study site (e.g., urgent care, primary care physician). An SAE was defined as any event that resulted in death, was immediately life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Any MAAEs | 0 | 1 | 0 | 1 | 3 | 2 | 1 | 0 |
| Any AEs Leading to Discontinuation from Study Vaccine/Study Withdrawal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any SAEs | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
Blood samples were collected to assess participants' immune response. GMC data are reported for the pseudoviral D614G variant. Data are reported in international units per milliliter (IU/mL).
| IU/mL | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Pseudoviral D614G; Baseline | 8 (NA to NA) | 8 (6 to 11) | 12 (4 to 33) | 421 (74 to 2383) | 455 (202 to 1028) | 87 (51 to 148) | 94 (29 to 301) | 114 (58 to 224) |
| Pseudoviral D614G; Day 15 | — | — | — | — | — | 1415 (927 to 2160) | 2019 (1179 to 3459) | 3474 (1577 to 7656) |
| Pseudoviral D614G; Day 29 | 36 (0 to 2715) | 9 (2 to 47) | 26 (6 to 107) | 1966 (592 to 6534) | 1949 (1026 to 3701) | 1741 (1001 to 3028) | 2202 (1170 to 4145) | 4200 (2274 to 7757) |
| Pseudoviral D614G; Day 57 | 42 (2 to 998) | 87 (0 to 1334270362) | 70 (11 to 452) | 2038 (676 to 6143) | 3563 (2083 to 6096) | — | — | — |
| Pseudoviral D614G; Day 91 | — | — | — | — | — | 1796 (1067 to 3024) | 1697 (840 to 3429) | 3427 (2113 to 5558) |
| Pseudoviral D614G; Day 181 | — | — | — | — | — | 1072 (450 to 2551) | 1534 (552 to 4260) | 3041 (1334 to 6932) |
| Pseudoviral D614G; Day 209 | 90 (2 to 3976) | — | 19 (4 to 85) | 1340 (100 to 17882) | 1402 (819 to 2402) | — | — | — |
| Pseudoviral D614G; Day 271 | — | — | — | — | — | 611 (246 to 1518) | 2158 (1198 to 3888) | 1965 (789 to 4893) |
| Pseudoviral D614G; Final Visit Cohort B (approx. Day 366) | — | — | — | — | — | 564 (232 to 1370) | 1924 (374 to 9900) | 2463 (870 to 6976) |
| Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394) | 60 (2 to 2088) | — | 14 (0 to 3129) | 1000 (10 to 100036) | 1324 (671 to 2609) | — | — | — |
Blood samples were collected to assess participants' immune response. GMC data are reported for the pseudoviral B.1.351 (beta) variant. Data are reported in arbitrary units per milliliter (AU/mL).
| AU/mL | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Pseudoviral B.1.351 (Beta); Baseline | 14 (NA to NA) | 14 (NA to NA) | 14 (13 to 15) | 402 (92 to 1761) | 442 (187 to 1042) | 38 (21 to 70) | 44 (15 to 130) | 60 (31 to 117) |
| Pseudoviral B.1.351 (Beta); Day 15 | — | — | — | — | — | 554 (370 to 829) | 1479 (824 to 2652) | 1692 (905 to 3162) |
| Pseudoviral B.1.351 (Beta); Day 29 | 17 (7 to 45) | 32 (0 to 1385422) | 17 (12 to 24) | 1926 (788 to 4710) | 1273 (615 to 2634) | 664 (447 to 986) | 1608 (940 to 2749) | 1768 (1061 to 2948) |
| Pseudoviral B.1.351 (Beta); Day 57 | 21 (6 to 75) | 452 (0 to 1024516559) | 27 (10 to 71) | 2292 (991 to 5300) | 3237 (2123 to 4936) | — | — | — |
| Pseudoviral B.1.351 (Beta); Day 91 | — | — | — | — | — | 560 (326 to 960) | 1079 (559 to 2083) | 1376 (838 to 2260) |
| Pseudoviral B.1.351 (Beta); Day 181 | — | — | — | — | — | 400 (142 to 1126) | 708 (219 to 2293) | 1202 (512 to 2819) |
| Pseudoviral B.1.351 (Beta); Day 209 | 97 (3 to 3668) | — | 14 (13 to 16) | 1372 (185 to 10163) | 1438 (780 to 2652) | — | — | — |
| Pseudoviral B.1.351 (Beta); Day 271 | — | — | — | — | — | 175 (30 to 1036) | 829 (252 to 2724) | 1129 (446 to 2858) |
| Pseudoviral B.1.351 (Beta); Final Visit Cohort B (approx. Day 366) | — | — | — | — | — | 213 (60 to 763) | 1532 (389 to 6036) | 1578 (604 to 4122) |
| Pseudoviral B.1.351 (Beta); Final Visit Cohort A1 and A2 (approx. Day 394) | 61 (3 to 1082) | — | 14 (NA to NA) | 1502 (45 to 50296) | 847 (467 to 1535) | — | — | — |
Blood samples were collected to assess participants' immune response. GMFR data are reported for the pseudoviral D614G variant.
| ratio | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Pseudoviral D614G; Day 15 | — | — | — | — | — | 16 (9 to 30) | 22 (9 to 50) | 28 (11 to 67) |
| Pseudoviral D614G; Day 29 | 4.6 (0.1 to 346.2) | 1.0 (0.6 to 1.7) | 2.2 (0.4 to 12.2) | 4.7 (1.4 to 15.9) | 4.4 (2.7 to 7) | 20 (10 to 41) | 24 (10 to 54) | 37 (17 to 77) |
| Pseudoviral D614G; Day 57 | 5.4 (0.2 to 127.2) | 10.1 (0 to 48765966.9) | 5.9 (0.5 to 65) | 4.8 (1.2 to 19.0) | 6.2 (3.8 to 10) | — | — | — |
| Pseudoviral D614G; Day 91 | — | — | — | — | — | 20 (10 to 41) | 17 (8 to 36) | 30 (19 to 47) |
| Pseudoviral D614G; Day 181 | — | — | — | — | — | 11 (4 to 30) | 12 (3 to 45) | 31 (14 to 70) |
| Pseudoviral D614G; Day 209 | 11.4 (0.3 to 506.9) | — | 1.4 (0.1 to 14.7) | 3.2 (0.7 to 14.2) | 2.7 (1.8 to 4.1) | — | — | — |
| Pseudoviral D614G; Day 271 | — | — | — | — | — | 5 (1 to 19) | 13 (2 to 71) | 20 (10 to 43) |
| Pseudoviral D614G; Final Visit Cohort B (approx. Day 366) | — | — | — | — | — | 6 (1 to 27) | 27 (5 to 147) | 25 (7 to 88) |
| Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394) | 7.7 (0.2 to 266.2) | — | 0.8 (0 to 329524.9) | 2.7 (0.2 to 42.6) | 1.9 (1.1 to 3.3) | — | — | — |
Blood samples were collected to assess participants' immune response. GMFR data are reported for the pseudoviral B.1.351 (beta) variant.
| ratio | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Pseudoviral B.1.351 (Beta); Day 15 | — | — | — | — | — | 14 (8 to 26) | 34 (16 to 72) | 25 (12 to 51) |
| Pseudoviral B.1.351 (Beta); Day 29 | 1.2 (0.5 to 3.2) | 2.3 (0 to 98958.7) | 1.2 (0.8 to 1.7) | 4.8 (1.6 to 14.0) | 3.2 (1.3 to 7.5) | 17 (10 to 31) | 37 (17 to 77) | 29 (16 to 54) |
| Pseudoviral B.1.351 (Beta); Day 57 | 1.5 (0.4 to 5.4) | 32.3 (0 to 73179754.2) | 1.9 (0.7 to 4.9) | 5.7 (1.4 to 22.7) | 5.6 (3.3 to 9.7) | — | — | — |
| Pseudoviral B.1.351 (Beta); Day 91 | — | — | — | — | — | 14 (7 to 27) | 23 (10 to 51) | 23 (15 to 35) |
| Pseudoviral B.1.351 (Beta); Day 181 | — | — | — | — | — | 10 (4 to 26) | 12 (1 to 98) | 24 (10 to 56) |
| Pseudoviral B.1.351 (Beta); Day 209 | 6.9 (0.2 to 262.0) | — | 1.0 (NA to NA) | 2.8 (0.7 to 11.6) | 2.9 (1.8 to 4.6) | — | — | — |
| Pseudoviral B.1.351 (Beta); Day 271 | — | — | — | — | — | 4 (2 to 8) | 12 (2 to 71) | 23 (11 to 45) |
| Pseudoviral B.1.351 (Beta); Final Visit Cohort B (approx. Day 366) | — | — | — | — | — | 5 (1 to 22) | 46 (5 to 409) | 31 (9 to 108) |
| Pseudoviral B.1.351 (Beta); Final Visit Cohorts A1 and A2 (approx. Day 394) | 4.4 (0.2 to 77.3) | — | 1.0 (0.6 to 1.5) | 3.0 (0.2 to 42.9) | 1.7 (0.9 to 3.2) | — | — | — |
Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G variant.
| Participants | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Pseudoviral D614G; Day 15 | — | — | — | — | — | 11 | 11 | 10 |
| Pseudoviral D614G; Day 29 | 1 | 0 | 2 | 3 | 10 | 11 | 11 | 11 |
| Pseudoviral D614G; Day 57 | 2 | 1 | 2 | 4 | 11 | — | — | — |
| Pseudoviral D614G; Day 91 | — | — | — | — | — | 10 | 10 | 12 |
| Pseudoviral D614G; Day 181 | — | — | — | — | — | 5 | 8 | 9 |
| Pseudoviral D614G; Day 209 | 2 | — | 0 | 1 | 5 | — | — | — |
| Pseudoviral D614G; Day 271 | — | — | — | — | — | 3 | 6 | 8 |
| Pseudoviral D614G; Final Visit Cohort B (approx. Day 366) | — | — | — | — | — | 3 | 5 | 6 |
| Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394) | 2 | — | 0 | 1 | 1 | — | — | — |
Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral B.1.351 (beta) variant.
| Participants | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Pseudoviral B.1.351 (Beta); Day 15 | — | — | — | — | — | 11 | 11 | 10 |
| Pseudoviral B.1.351 (Beta); Day 29 | 0 | 1 | 0 | 3 | 9 | 11 | 11 | 11 |
| Pseudoviral B.1.351 (Beta); Day 57 | 1 | 2 | 1 | 3 | 9 | — | — | — |
| Pseudoviral B.1.351 (Beta); Day 91 | — | — | — | — | — | 9 | 10 | 12 |
| Pseudoviral B.1.351 (Beta); Day 181 | — | — | — | — | — | 4 | 8 | 8 |
| Pseudoviral B.1.351 (Beta); Day 209 | 2 | — | 0 | 1 | 5 | — | — | — |
| Pseudoviral B.1.351 (Beta); Day 271 | — | — | — | — | — | 2 | 5 | 9 |
| Pseudoviral B.1.351 (Beta); Final Visit Cohort B (approx. Day 366) | — | — | — | — | — | 3 | 4 | 7 |
| Pseudoviral B.1.351 (Beta); Final Visit Cohorts A1 and A2 (approx. Day 394) | 2 | — | 0 | 1 | 1 | — | — | — |
Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G Variant, B.1.351 Variant, B.1.617.2 Variant, BA.1 Variant for the GMC ratio of ARCT-165 vs ARCT-154 and ARCT-021 vs ARCT-154. Data are reported for the ARCT-165 and ARCT-021 arms (vs ARCT-154 values).
| ratio | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A2: ARCT-021 | Cohort B: ARCT-021 | Cohort B: ARCT-165 |
|---|---|---|---|---|---|
| Pseudoviral D614G; Day 15 | — | — | — | 0.41 (0.179 to 0.924) | 0.58 (0.240 to 1.405) |
| Pseudoviral D614G; Day 29 | 1.38 (0.108 to 17.701) | 0.35 (0.054 to 2.225) | 1.01 (0.301 to 3.377) | 0.41 (0.190 to 0.903) | 0.52 (0.229 to 1.203) |
| Pseudoviral D614G; Day 57 | 0.60 (0.035 to 10.082) | 1.23 (0.046 to 33.164) | 0.57 (0.210 to 1.559) | — | — |
| Pseudoviral D614G; Day 91 | — | — | — | 0.52 (0.269 to 1.021) | 0.50 (0.225 to 1.089) |
| Pseudoviral D614G; Day 181 | — | — | — | 0.35 (0.115 to 1.082) | 0.50 (0.151 to 1.686) |
| Pseudoviral D614G; Day 209 | 4.65 (0.115 to 188.134) | — | 0.96 (0.251 to 3.629) | — | — |
| Pseudoviral D614G; Day 271 | — | — | — | 0.31 (0.086 to 1.123) | 1.10 (0.377 to 3.199) |
| Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394) | 4.20 (0.038 to 458.249) | — | 0.76 (0.139 to 4.106) | — | — |
| Pseudoviral D614G; Final Visit Cohort B (approx. Day 366) | — | — | — | 0.23 (0.064 to 0.825) | 0.78 (0.162 to 3.771) |
| Pseudoviral B.1.351; Day 15 | — | — | — | 0.33 (0.165 to 0.650) | 0.87 (0.392 to 1.951) |
| Pseudoviral B.1.351; Day 29 | 1.03 (0.575 to 1.846) | 1.92 (0.426 to 8.609) | 1.51 (0.418 to 5.476) | 0.38 (0.204 to 0.691) | 0.91 (0.452 to 1.827) |
| Pseudoviral B.1.351; Day 57 | 0.78 (0.227 to 2.712) | 16.96 (1.632 to 176.241) | 0.71 (0.325 to 1.545) | — | — |
| Pseudoviral B.1.351; Day 91 | — | — | — | 0.41 (0.205 to 0.808) | 0.78 (0.365 to 1.684) |
| Pseudoviral B.1.351; Day 181 | — | — | — | 0.33 (0.099 to 1.117) | 0.59 (0.155 to 2.238) |
| Pseudoviral B.1.351; Day 209 | 6.77 (0.210 to 218.085) | — | 0.95 (0.242 to 3.759) | — | — |
| Pseudoviral B.1.351; Day 271 | — | — | — | 0.16 (0.032 to 0.742) | 0.73 (0.192 to 2.813) |
| Pseudoviral B.1.351; Final Visit Cohorts A1 and A2 (approx. Day 394) | 4.37 (0.102 to 187.648) | — | 1.77 (0.433 to 7.256) | — | — |
| Pseudoviral B.1.351; Final Visit Cohort B (approx. Day 366) | — | — | — | 0.14 (0.034 to 0.540) | 0.97 (0.234 to 4.022) |
| Pseudoviral B.1.617.2; Day 15 | — | — | — | 0.43 (0.208 to 0.900) | 0.69 (0.293 to 1.611) |
| Pseudoviral B.1.617.2; Day 29 | 2.45 (0.183 to 32.786) | 0.77 (0.268 to 2.241) | 1.17 (0.386 to 3.544) | 0.47 (0.231 to 0.947) | 0.66 (0.305 to 1.447) |
| Pseudoviral B.1.617.2; Day 57 | 1.78 (0.293 to 10.846) | 1.42 (0.552 to 3.644) | 0.92 (0.345 to 2.469) | — | — |
| Pseudoviral B.1.617.2; Day 91 | — | — | — | 0.68 (0.266 to 1.740) | 0.61 (0.277 to 1.331) |
| Pseudoviral B.1.617.2; Day 181 | — | — | — | 0.46 (0.142 to 1.466) | 0.82 (0.274 to 2.465) |
| Pseudoviral B.1.617.2; Day 209 | 3.26 (0.388 to 27.333) | — | 0.59 (0.116 to 3.053) | — | — |
| Pseudoviral B.1.617.2; Day 271 | — | — | — | 0.41 (0.114 to 1.465) | 1.30 (0.482 to 3.497) |
| Pseudoviral B.1.617.2; Final Visit Cohorts A1 and A2 (approx. Day 394) | 2.18 (0.317 to 15.035) | — | 0.84 (0.179 to 3.905) | — | — |
| Pseudoviral B.1.617.2; Final Visit Cohort B (approx. Day 366) | — | — | — | 0.35 (0.095 to 1.282) | 1.30 (0.279 to 6.100) |
| Pseudoviral BA.1 Variant; Day 15 | — | — | — | 0.34 (0.159 to 0.740) | 1.18 (0.501 to 2.799) |
| Pseudoviral BA.1 Variant; Day 29 | 1.52 (0.677 to 3.427) | 1.05 (0.832 to 1.336) | 1.18 (0.369 to 3.760) | 0.36 (0.182 to 0.703) | 1.06 (0.485 to 2.310) |
| Pseudoviral BA.1 Variant; Day 57 | 1.15 (0.612 to 2.153) | 9.73 (0.286 to 331.151) | 0.74 (0.287 to 1.913) | — | — |
| Pseudoviral BA.1 Variant; Day 91 | — | — | — | 0.35 (0.182 to 0.666) | 0.82 (0.361 to 1.856) |
| Pseudoviral BA.1 Variant; Day 181 | — | — | — | 0.22 (0.047 to 1.032) | 0.82 (0.194 to 3.479) |
| Pseudoviral BA.1 Variant; Day 209 | 8.15 (0.701 to 94.646) | — | 1.38 (0.260 to 7.365) | — | — |
| Pseudoviral BA.1 Variant; Day 271 | — | — | — | 0.20 (0.038 to 1.011) | 1.27 (0.369 to 4.347) |
| Pseudoviral BA.1 Variant; Final Visit Cohorts A1 and A2 (approx. Day 394) | 3.69 (0.190 to 71.730) | — | 1.91 (0.223 to 16.385) | — | — |
| Pseudoviral BA.1 Variant; Final Visit Cohort B (approx. Day 366) | — | — | — | 0.11 (0.020 to 0.562) | 0.87 (0.162 to 4.620) |
Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G Variant, B.1.351 Variant, B.1.617.2 Variant, BA.1 Variant for the GMC ratio of ARCT-021 vs ARCT-165. Data are reported for the ARCT-021 arm (vs ARCT-165 values).
| ratio | Cohort A1: ARCT-021 | Cohort B: ARCT-021 |
|---|---|---|
| Pseudoviral D614G; Day 15 | — | 0.70 (0.368 to 1.335) |
| Pseudoviral D614G; Day 29 | 4.00 (0.063 to 252.690) | 0.79 (0.358 to 1.746) |
| Pseudoviral D614G; Day 57 | 0.48 (0.004 to 53.354) | — |
| Pseudoviral D614G; Day 91 | — | 1.06 (0.460 to 2.432) |
| Pseudoviral D614G; Day 181 | — | 0.70 (0.186 to 2.624) |
| Pseudoviral D614G; Day 209 | NA (NA to NA) | — |
| Pseudoviral D614G; Day 271 | — | 0.28 (0.117 to 0.684) |
| Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394) | NA (NA to NA) | — |
| Pseudoviral D614G; Final Visit Cohort B (approx. Day 366) | — | 0.29 (0.062 to 1.377) |
| Pseudoviral B.1.351; Day 15 | — | 0.37 (0.192 to 0.731) |
| Pseudoviral B.1.351; Day 29 | 0.54 (0.061 to 4.779) | 0.41 (0.221 to 0.774) |
| Pseudoviral B.1.351; Day 57 | 0.05 (0.004 to 0.609) | — |
| Pseudoviral B.1.351; Day 91 | — | 0.52 (0.232 to 1.160) |
| Pseudoviral B.1.351; Day 181 | — | 0.56 (0.122 to 2.616) |
| Pseudoviral B.1.351; Day 209 | NA (NA to NA) | — |
| Pseudoviral B.1.351; Day 271 | — | 0.21 (0.037 to 1.223) |
| Pseudoviral B.1.351; Final Visit Cohorts A1 and A2 (approx. Day 394) | NA (NA to NA) | — |
| Pseudoviral B.1.351; Final Visit Cohort B (approx. Day 366) | — | 0.14 (0.028 to 0.688) |
| Pseudoviral B.1.617.2; Day 15 | — | 0.63 (0.328 to 1.210) |
| Pseudoviral B.1.617.2; Day 29 | 3.16 (0.028 to 357.696) | 0.70 (0.365 to 1.357) |
| Pseudoviral B.1.617.2; Day 57 | 1.26 (0.053 to 29.735) | — |
| Pseudoviral B.1.617.2; Day 91 | — | 0.68 (0.266 to 1.740) |
| Pseudoviral B.1.617.2; Day 181 | — | 0.56 (0.159 to 1.948) |
| Pseudoviral B.1.617.2; Day 209 | NA (NA to NA) | — |
| Pseudoviral B.1.617.2; Day 271 | — | 0.31 (0.109 to 0.904) |
| Pseudoviral B.1.617.2; Final Visit Cohorts A1 and A2 (approx. Day 394) | NA (NA to NA) | — |
| Pseudoviral B.1.617.2; Final Visit Cohort B (approx. Day 366) | — | 0.27 (0.065 to 1.097) |
| Pseudoviral BA.1 Variant; Day 15 | — | 0.29 (0.156 to 0.537) |
| Pseudoviral BA.1 Variant; Day 29 | 1.45 (0.304 to 6.868) | 0.34 (0.174 to 0.654) |
| Pseudoviral BA.1 Variant; Day 57 | 0.12 (0.003 to 4.660) | — |
| Pseudoviral BA.1 Variant; Day 91 | — | 0.43 (0.182 to 0.996) |
| Pseudoviral BA.1 Variant; Day 181 | — | 0.27 (0.059 to 1.217) |
| Pseudoviral BA.1 Variant; Day 209 | NA (NA to NA) | — |
| Pseudoviral BA.1 Variant; Day 271 | — | 0.15 (0.042 to 0.570) |
| Pseudoviral BA.1 Variant; Final Visit Cohorts A1 and A2 (approx. Day 394) | NA (NA to NA) | — |
| Pseudoviral BA.1 Variant; Final Visit Cohort B (approx. Day 366) | — | 0.12 (0.024 to 0.622) |
Spike binding antibody levels expressed as GMCs are reported for ancestral, D614G, and B.1.351 variants and RBD binding antibodies for ancestral strain.
| AU/mL | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Baseline; RBD (Ancestral) | 0.0 (0.0 to 0.0) | 0.1 (0.0 to 1.2) | 0.1 (0.0 to 0.7) | 34 (9 to 124) | 29 (14 to 60) | 9 (6 to 14) | 9 (4 to 21) | 10 (6 to 16) |
| Baseline; Spike (Ancestral) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.4) | 0.3 (0.0 to 1.7) | 44 (13 to 156) | 49 (27 to 90) | 18 (12 to 27) | 17 (8 to 39) | 19 (11 to 33) |
| Baseline; Spike (D614G) | 0.0 (0.0 to 0.2) | 0.1 (0.0 to 0.9) | 0.2 (0.0 to 1.7) | 47 (14 to 161) | 52 (29 to 95) | 19 (13 to 27) | 18 (8 to 40) | 20 (11 to 35) |
| Baseline; Spike (B.1.351) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.5) | 0.2 (0.0 to 1.6) | 30 (11 to 77) | 32 (19 to 56) | 8 (6 to 12) | 8 (4 to 17) | 9 (5 to 16) |
| Day 57; RBD (Ancestral) | 3.4 (0.1 to 133.7) | 34.5 (0.0 to 13491400) | 8.2 (1.2 to 54.5) | 138 (49 to 386) | 186 (128 to 270) | — | — | — |
| Day 57; Spike (Ancestral) | 10.6 (0.4 to 285.1) | 52.4 (0.0 to 3217076.2) | 19.1 (3.3 to 108.8) | 181 (65 to 504) | 265 (196 to 358) | — | — | — |
| Day 57; Spike (D614G) | 10.7 (0.4 to 276.8) | 55.8 (0.0 to 1948962.5) | 19.8 (3.6 to 110.4) | 187 (69 to 511) | 277 (205 to 375) | — | — | — |
| Day 57; Spike (B.1.351) | 5.0 (0.2 to 147.4) | 61.1 (0.0 to 7370140.4) | 5.8 (0.6 to 58.4) | 119 (51 to 278) | 147 (112 to 193) | — | — | — |
| Day 15; RBD (Ancestral) | — | — | — | — | — | 91 (57 to 146) | 171 (115 to 254) | 221 (118 to 415) |
| Day 15; Spike (Ancestral) | — | — | — | — | — | 138 (89 to 215) | 231 (150 to 355) | 290 (164 to 514) |
| Day 15; Spike (D614G) | — | — | — | — | — | 142 (92 to 217) | 235 (154 to 359) | 296 (166 to 529) |
| Day 15; Spike (B.1.351) | — | — | — | — | — | 57 (40 to 82) | 117 (79 to 172) | 123 (71 to 212) |
Spike binding antibody levels expressed as GMFRs are reported for ancestral, D614G, and B.1.351 variants and RBD binding antibody levels expressed as GMFR for ancestral strain.
| ratio | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Day 57; RBD (Ancestral) | 129 (6 to 2894) | 286 (0 to 46860600000) | 110 (8 to 1560) | 4.1 (1.4 to 12.3) | 4.9 (3.0 to 8.0) | — | — | — |
| Day 57; Spike (Ancestral) | 231 (10 to 5236) | 807 (0 to 184116000000) | 76 (5 to 1279) | 4.1 (1.6 to 10.8) | 4.2 (2.8 to 6.3) | — | — | — |
| Day 57; Spike (D614G) | 237 (10 to 5730) | 667 (0 to 2176320000000) | 84 (5 to 1404) | 4.0 (1.5 to 10.4) | 4.1 (2.8 to 6.1) | — | — | — |
| Day 57; Spike (B.1.351) | 136 (5 to 4083) | 1076 (0 to 12500400000000) | 32 (3 to 361) | 4.0 (1.6 to 10.2) | 3.6 (2.4 to 5.4) | — | — | — |
| Day 15; RBD (Ancestral) | — | — | — | — | — | 10 (6 to 16) | 19 (10 to 38) | 21 (11 to 40) |
| Day 15; Spike (Ancestral) | — | — | — | — | — | 8 (5 to 13) | 13 (7 to 25) | 14 (8 to 26) |
| Day 15; Spike (D614G) | — | — | — | — | — | 8 (5 to 13) | 13 (7 to 25) | 14 (7 to 26) |
| Day 15; Spike (B.1.351) | — | — | — | — | — | 7 (4 to 11) | 15 (8 to 27) | 13 (7 to 22) |
Data are reported for ancestral, D614G, and B.1.351 variants for Spike binding antibodies and ancestral for RBD binding antibodies.
| Participants | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Day 57; RBD (Ancestral) | 4 | 2 | 4 | 3 | 9 | — | — | — |
| Day 57; Spike (Ancestral) | 4 | 2 | 4 | 3 | 8 | — | — | — |
| Day 57; Spike (D614G) | 4 | 2 | 4 | 3 | 8 | — | — | — |
| Day 57; Spike (B.1.351) | 4 | 2 | 4 | 3 | 6 | — | — | — |
| Day 15; RBD (Ancestral) | — | — | — | — | — | 11 | 11 | 10 |
| Day 15; Spike (Ancestral) | — | — | — | — | — | 9 | 10 | 10 |
| Day 15; Spike (D614G) | — | — | — | — | — | 9 | 11 | 10 |
| Day 15; Spike (B.1.351) | — | — | — | — | — | 9 | 11 | 10 |
Collected over Through Final Visit (365 days after last study vaccine dose); up to a maximum of approximately 394 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A1: ARCT-021 | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Cohort A1: ARCT-165 | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Cohort A1: ARCT-154 | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Cohort A2: ARCT-021 | 0/6 (0%) | 1/6 (16.7%) | 4/6 (66.7%) |
| Cohort A2: ARCT-154 | 0/18 (0%) | 0/18 (0%) | 15/18 (83.3%) |
| Cohort B: ARCT-021 | 0/12 (0%) | 1/12 (8.3%) | 9/12 (75%) |
| Cohort B: ARCT-165 | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Cohort B: ARCT-154 | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Event | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Spontaneous abortionPregnancy, puerperium and perinatal conditions | 0/3 | 0/1 | 0/2 | 1/4 | 0/10 | 0/9 | 0/6 | 0/7 |
| DepressionPsychiatric disorders | 0/4 | 0/4 | 0/4 | 0/6 | 0/18 | 1/12 | 0/12 | 0/12 |
| Event | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/4 | 0/4 | 0/4 | 4/6 | 15/18 | 0/12 | 1/12 | 2/12 |
| COVID-19Infections and infestations | 0/4 | 0/4 | 0/4 | 2/6 | 6/18 | 4/12 | 6/12 | 6/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/4 | 1/4 | 0/4 | 1/6 | 1/18 | 2/12 | 0/12 | 2/12 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/4 | 1/4 | 0/4 | 1/6 | 0/18 | 2/12 | 1/12 | 2/12 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/4 | 0/4 | 0/4 | 0/6 | 2/18 | 2/12 | 1/12 | 1/12 |
| HeadacheNervous system disorders | 2/4 | 0/4 | 0/4 | 1/6 | 5/18 | 1/12 | 1/12 | 1/12 |
| FatigueGeneral disorders | 2/4 | 0/4 | 0/4 | 0/6 | 1/18 | 1/12 | 1/12 | 1/12 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 2/4 | 1/4 | 0/6 | 2/18 | 2/12 | 1/12 | 2/12 |
| Fungal infectionInfections and infestations | 0/4 | 0/4 | 1/4 | 0/6 | 0/18 | 0/12 | 0/12 | 0/12 |
| PericoronitisInfections and infestations | 1/4 | 0/4 | 0/4 | 0/6 | 0/18 | 0/12 | 0/12 | 0/12 |
Measured in the Safety Set (SS): The SS included all randomized participants who received at least one dose of the study vaccine. Assignment of participants to study vaccine group was based on the study vaccine actually received.
| Age, Continuous(years) | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 46 ± 17 | 34 ± 10 | 50 ± 17 | 33 ± 9 | 31 ± 8 | 44 ± 16 | 50 ± 13 | 44 ± 13 | 41 ± 14 |
| Sex: Female, Male(Participants) | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 2 | 4 | 10 | 9 | 6 | 7 | 42 |
| Male | 1 | 3 | 2 | 2 | 8 | 3 | 6 | 5 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 3 |
| Not Hispanic or Latino | 4 | 4 | 4 | 6 | 17 | 10 | 12 | 12 | 69 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort A1: ARCT-021 | Cohort A1: ARCT-165 | Cohort A1: ARCT-154 | Cohort A2: ARCT-021 | Cohort A2: ARCT-154 | Cohort B: ARCT-021 | Cohort B: ARCT-165 | Cohort B: ARCT-154 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 | 0 | 0 | 2 | 2 | 2 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 5 | 16 | 1 | 2 | 0 | 27 |
| White | 2 | 0 | 1 | 1 | 2 | 9 | 8 | 10 | 33 |
| More than one race | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will only be made available to study investigators at this time.
Ran from Aug 2021 to primary completion in Dec 2023, 27 months.
Results were first posted in Oct 2025, 1 year 9 months after primary completion. A results delay was requested in Dec 2024.
Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 27 months is above that.
Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SARS-CoV-2 mRNA Vaccine ARCT-021
Arcturus Therapeutics, Inc.